Yatharth Hospital & Trauma Care Services has approved a major Rs 3,150 crore capital raise via a preferential issue of shares and warrants to Cyprus-based Rasmalai Limited. This deal grants the investor a 24.87% stake on a fully diluted basis and includes new governance rights, such as board representation. The company will also hike its authorized share capital to accommodate the issuance, marking a significant strengthening of its balance sheet ahead of an EGM scheduled for October 15, 2026.
Yatharth Hospital Announces Rs 3,150 Crore Strategic Investment
Total Consideration: Rs 3,150 crore | Post-Issue Stake: 24.87% (fully diluted)
Reader Takeaway: The significant capital infusion strengthens the balance sheet, though investors should note the dilution and governance changes.
What just happened
Yatharth Hospital & Trauma Care Services Ltd has formally approved a massive preferential issue of equity shares and warrants to Rasmalai Limited (Cyprus). The company will issue over 13 million equity shares and nearly 19 million warrants at an issue price of Rs 985.17 per security. This capital injection of Rs 3,150 crore is set to make Rasmalai Limited a major shareholder with a 24.87% stake upon full conversion.
Why this matters
This transaction is a major liquidity event that provides Yatharth Hospital with substantial cash reserves to fund growth and expansion. Beyond the capital, the company is altering its corporate governance structure by allowing Rasmalai Limited to nominate two non-executive directors and securing investor oversight on key corporate matters. An 'Upside Share Arrangement' involving promoter Mr. Ajay Tyagi has also been disclosed, linking potential promoter payouts to the investor's performance returns.
What changes now
The company is increasing its authorized share capital from Rs 115 crore to Rs 150 crore to support the new issuance. Shareholders are scheduled to vote on these proposals at an Extraordinary General Meeting (EGM) on October 15, 2026. The approval of this EGM is a critical condition for the transaction to proceed.
Risks to watch
Investors should monitor the successful fulfillment of conditions precedent, including regulatory and shareholder approvals. The introduction of reserved matters and board seats for the new investor could alter the existing decision-making dynamic. Furthermore, the dilution resulting from this preferential issue should be factored into long-term valuation models.
What to track next
Watch for the EGM outcome on October 15, 2026, and any subsequent regulatory filings regarding the receipt of funds and the allotment of the securities. Any updates regarding the 'Upside Share Arrangement' will also be relevant for assessing promoter-investor alignment.